| Date | Time | Source | Headline | Symbol | Company |
| 04/20/2022 | 11:15PM | TipRanks | Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and AbbVie (ABBV) | NYSE:ABBV | AbbVie Inc |
| 04/20/2022 | 8:57AM | Dow Jones News | Dragonfly Expands Research Collaboration With AbbVie | NYSE:ABBV | AbbVie Inc |
| 04/20/2022 | 8:00AM | PR Newswire (US) | Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases | NYSE:ABBV | AbbVie Inc |
| 04/20/2022 | 5:45AM | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of AbbVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 6, 2022 - (NYSE: ABBV) | NYSE:ABBV | AbbVie Inc |
| 04/19/2022 | 12:08PM | TipRanks | AbbVie: Why It’s an Excellent Recession-Resistant Stock | NYSE:ABBV | AbbVie Inc |
| 04/19/2022 | 8:30AM | PR Newswire (US) | Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting | NYSE:ABBV | AbbVie Inc |
| 04/15/2022 | 5:45AM | PR Newswire (US) | ABBV SHAREHOLDER ALERT: Jakubowitz Law Reminds AbbVie Shareholders of a Lead Plaintiff Deadline of June 6, 2022 | NYSE:ABBV | AbbVie Inc |
| 04/14/2022 | 11:26PM | TipRanks | AbbVie (ABBV) Gets a Buy Rating from Wells Fargo | NYSE:ABBV | AbbVie Inc |
| 04/14/2022 | 8:00AM | PR Newswire (US) | AbbVie to Host First-Quarter 2022 Earnings Conference Call | NYSE:ABBV | AbbVie Inc |
| 04/13/2022 | 6:53PM | PR Newswire (US) | AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) | NYSE:ABBV | AbbVie Inc |
| 04/13/2022 | 5:26PM | Business Wire | Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) | NYSE:ABBV | AbbVie Inc |
| 04/13/2022 | 10:19AM | Dow Jones News | Abbvie Vice Chairman Severino Departs for Flagship Pioneering | NYSE:ABBV | AbbVie Inc |
| 04/13/2022 | 9:16AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NYSE:ABBV | AbbVie Inc |
| 04/13/2022 | 8:00AM | PR Newswire (US) | BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval | NYSE:ABBV | AbbVie Inc |
| 04/13/2022 | 5:45AM | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of AbbVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 6, 2022 - (NYSE: ABBV) | NYSE:ABBV | AbbVie Inc |
| 04/12/2022 | 9:23AM | TipRanks | AbbVie: Great Company, Future Upside Likely Weakened | NYSE:ABBV | AbbVie Inc |
| 04/12/2022 | 8:56AM | Dow Jones News | AbbVie Reports Promising Mid-Stage Trial Data for Blood-Cancer Treatment | NYSE:ABBV | AbbVie Inc |
| 04/12/2022 | 8:00AM | PR Newswire (US) | AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis | NYSE:ABBV | AbbVie Inc |
| 04/05/2022 | 9:29AM | Dow Jones News | Allergan's Twice-Daily Vuity Study Hits Main Endpoint in Presbyopia | NYSE:ABBV | AbbVie Inc |
| 04/05/2022 | 8:30AM | PR Newswire (US) | Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia) | NYSE:ABBV | AbbVie Inc |
| 04/04/2022 | 5:17PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 04/04/2022 | 5:16PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 04/04/2022 | 12:39PM | Business Wire | Resorts World Las Vegas Secures First-of-its-Kind Agreement With Allergan Aesthetics | NYSE:ABBV | AbbVie Inc |
| 04/04/2022 | 8:37AM | Edgar (US Regulatory) | Notice of Exempt Solicitation. Definitive Material. (px14a6g) | NYSE:ABBV | AbbVie Inc |
| 04/01/2022 | 12:46PM | TipRanks | 3 Stocks To Hold For Decades | NYSE:ABBV | AbbVie Inc |
| 04/01/2022 | 3:14AM | TipRanks | 3 Top Healthcare Stocks to Make Your Portfolio Smarter | NYSE:ABBV | AbbVie Inc |
| 03/30/2022 | 4:41PM | Edgar (US Regulatory) | Notice of Exempt Solicitation. Definitive Material. (px14a6g) | NYSE:ABBV | AbbVie Inc |
| 03/29/2022 | 8:00AM | PR Newswire (US) | AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting | NYSE:ABBV | AbbVie Inc |
| 03/27/2022 | 1:51PM | Benzinga | This Biopharma Company Has A Better 6-Month Return Than AMD, Nvidia, Ford, Wells Fargo And Bank Of America | NYSE:ABBV | AbbVie Inc |
| 03/25/2022 | 5:10PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |